In clinical development and generic drug approval, a “comparator drug” is one of the most important — and most misunderstood — procurement decisions a team will make. Here’s what a comparator drug actually is, how it differs from related terms like Reference Listed Drug, and what to look for when sourcing one.
What Is a Comparator Drug?
A comparator drug is an already-approved medicine used as the benchmark against which a new or generic drug is tested — most commonly in bioequivalence studies, clinical trials, or quality comparisons. The comparator provides the known, validated standard that the test product must match or outperform.
The term is broader than Reference Listed Drug (RLD): an RLD is a specific FDA-designated comparator used for U.S. ANDA submissions, while “comparator drug” is used more generally across global regulatory contexts, including clinical trials that test a new drug against an existing standard of care.
Why Comparator Drugs Matter
Every comparative study — bioequivalence, clinical non-inferiority, or head-to-head efficacy — is only as reliable as the comparator behind it. If the comparator is the wrong product, an unverified batch, or lacks proper documentation, the resulting data can be challenged or rejected by regulators, no matter how well the study itself was executed.
- Bioequivalence studies rely on the comparator’s pharmacokinetic profile as the benchmark
- Clinical trials use comparators to establish relative safety and efficacy
- Regulatory submissions require documented proof the comparator matches the correct approved product
Sourcing Considerations
Sourcing a comparator drug carries the same core challenges as sourcing an RLD: confirming the exact approved product and formulation, securing batch-specific documentation, and establishing a clean chain of custody. For international trials, teams often need a comparator sourced and documented to match the regulatory expectations of multiple jurisdictions at once, which adds another layer of verification.
How Chemigran Supports Comparator Sourcing
Chemigran sources comparator drugs and Reference Listed Drugs with the same rigor: verified product identity, Certificate of Analysis and batch documentation, and full chain-of-custody records. Our team works directly with regulatory affairs and clinical operations teams who need this handled correctly the first time.
FAQ
Is a comparator drug the same as an RLD?
Not exactly — an RLD is a specific FDA designation used for U.S. generic drug approval, while “comparator drug” is a broader term used across clinical trials and international regulatory contexts. An RLD is one type of comparator drug.
Who typically sources comparator drugs?
Generic drug developers, clinical trial sponsors, and CROs running bioequivalence or comparative efficacy studies.
What documentation should accompany a comparator drug?
A Certificate of Analysis for the specific batch, confirmation of the correct approved product match, and chain-of-custody documentation.
Need a properly sourced and documented comparator drug for your study? Contact the Chemigran team or see our related guide on what a Reference Listed Drug is.
